CTOs on the Move

Detroit Wayne Mental Health Authority

www.dwihn.org

 
DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dwihn.org
  • 707, West Milwaukee Avenue
    Detroit, MI USA 48202
  • Phone: 313.344.9099

Executives

Name Title Contact Details

Similar Companies

SK Biopharmaceuticals

SK Biopharmaceuticals is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Formulated Solutions

Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.

Highlands Community Services

Current Operational Status: A Letter from the Executive Director July 6, 2020 These last few [...]

L.B. Bohle

L.B. Bohle, LLC is a Warminster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.